Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma

British Journal of Cancer

Volumn 102, Issue 9, 2010, Pages 1378-1383

  Takeshita, H ^a   Ichikawa, D ^a   Komatsu, S ^a   Tsujiura, M ^a   Kosuga, T ^a   Deguchi, K ^a   Konishi, H ^a   Morimura, R ^a   Shiozaki, A ^a   Fujiwara, H ^a   Okamoto, K ^a   Otsuji, E ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Biomarker; Copy number; Cyclin D1; Oesophageal cancer; Plasma

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; DNA; DOPAMINE 2 RECEPTOR;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; DNA ISOLATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE AMPLIFICATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PLASMA; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; VALIDATION STUDY;

CARCINOMA, SQUAMOUS CELL; CYCLIN D1; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTORS, DOPAMINE D2; RECURRENCE; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 77951667933     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605657     Document Type: Article

References (30)

1. Adélaide J, Monges G, Dérdérian C, Seitz JF, Birnbaum D (1995) Oesophageal cancer and amplification of the human cyclin D gene CCND1/PRAD1. Br J Cancer 71: 64-68
2. Chiang PW, Beer DG, Wei WL, Orringer MB, Kurnit DM (1999) Detection of erbB-2 amplifications in tumors and sera from esophageal carcinoma patients. Clin Cancer Res 5: 1381-1386
3. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz Jr LA (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14: 985-990
4. Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349: 2241-2252
5. Fleischhacker M, Schmidt B (2007) Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 1775: 181-232
6. Gotoh T, Hosoi H, Iehara T, Kuwahara Y, Osone S, Tsuchiya K, Ohira M, Nakagawara A, Kuroda H, Sugimoto T (2005) Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction. J Clin Oncol 23: 5205-5210
7. Gratas C, Tohma Y, Barnas C, Taniere P, Hainaut P, Ohgaki H (1998) Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res 58: 2057-2062
8. Hiyama T, Yoshihara M, Tanaka S, Chayama K (2007) Genetic polymorphisms and esophageal cancer risk. Int J Cancer 121: 1643-1658
9. Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC (1990) Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 87: 9958-9961
10. Ichikawa D, Koike H, Ikoma H, Ikoma D, Tani N, Otsuji E, Kitamura K, Yamagishi H (2004) Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer. Anticancer Res 24: 2477-2481
11. Imoto I, Yang ZQ, Pimkhaokham A, Tsuda H, Shimada Y, Imamura M, Ohki M, Inazawa J (2001) Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res 61: 6629-6634
12. Jain M, Kumar S, Upadhyay R, Lal P, Tiwari A, Ghoshal UC, Mittal B (2007) Influence of apoptosis (BCL2, FAS), cell cycle (CCND1) and growth factor (EGF, EGFR) genetic polymorphisms on survival outcome: an exploratory study in squamous cell esophageal cancer. Cancer Biol Ther 6: 1553-1558
13. Jiang W, Kahn SM, Tomita N, Zhang YJ, Lu SH, Weinstein IB (1992) Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 52: 2980-2983
14. Johnson PJ, Lo YM (2002) Plasma nucleic acids in the diagnosis and management of malignant disease. Clin Chem 48: 1186-1193
15. Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B, Nishio K (2006) Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 12: 3915-3921 (Pubitemid 44078075)
16. Koike H, Ichikawa D, Ikoma H, Otsuji E, Kitamura K, Yamagishi H (2004) Comparison of methylation-specific polymerase chain reaction (MSP) with reverse transcriptase-polymerase chain reaction (RT-PCR) in peripheral blood of gastric cancer patients. J Surg Oncol 87: 182-186
17. Komatsu S, Imoto I, Tsuda H, Kozaki KI, Muramatsu T, Shimada Y, Aiko S, Yoshizumi Y, Ichikawa D, Otsuji E, Inazawa J (2009) Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis 30: 1139-1146
18. Kyomoto R, Kumazawa H, Toda Y, Sakaida N, Okamura A, Iwanaga M, Shintaku M, Yamashita T, Hiai H, Fukumoto M (1997) Cyclin-D1-gene amplification is a more potent prognostic factor than its protein over-expression in human head-and-neck squamous-cell carcinoma. Int J Cancer 74: 576-581
19. Lam AK (2000) Molecular biology of esophageal squamous cell carcinoma. Crit Rev Oncol Hematol 33: 71-90
20. Lu SH, Hsieh LL, Luo FC, Weinstein IB (1988) Amplification of the EGF receptor and c-myc genes in human esophageal cancers. Int J Cancer 42: 502-505
21. Park KU, Lee HE, Park do J, Jung EJ, Song J, Kim HH, Choe G, Kim WH, Lee HS (2009) MYC quantitation in cell-free plasma DNA by real-time PCR for gastric cancer diagnosis. Clin Chem Lab Med 47: 530-536
22. Sai S, Ichikawa D, Tomita H, Ikoma D, Tani N, Ikoma H, Kikuchi S, Fujiwara H, Ueda Y, Otsuji E (2007) Quantification of plasma cell-free DNA in patients with gastric cancer. Anticancer Res 27: 2747-2751
23. Sato-Kuwabara Y, Neves JI, Fregnani JH, Sallum RA, Soares FA (2009) Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using fluorescence in situ hybridization (FISH) and immunohistochemistry. BMC Cancer 9: 6
24. Schwarzenbach H, Alix-Panabières C, Müller I, Letang N, Vendrell JP, Rebillard X, Pantel K (2009) Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 15: 1032-1038
25. Shinozaki H, Ozawa S, Ando N, Tsuruta H, Terada M, Ueda M, Kitajima M (1996) Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. Clin Cancer Res 2: 1155-1161
26. Skvortsova TE, Rykova EY, Tamkovich SN, Bryzgunova OE, Starikov AV, Kuznetsova NP, Vlassov VV, Laktionov PP (2006) Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer 94: 1492-1495
27. Sobin LH, Fleming ID (2002) TNM Classification of Malignant Tumors. 6th edn. Wiley-Liss: New York
28. Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, Roz E, Cirenei N, Bellomi M, Pelosi G, Pierotti MA, Pastorino U (2003) Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21: 3902-3908
29. Tani N, Ichikawa D, Ikoma D, Tomita H, Sai S, Ikoma H, Okamoto K, Ochiai T, Ueda Y, Otsuji E, Yamagishi H, Miura N, Shiota G (2007) Circulating cell-free mRNA in plasma as a tumor marker for patients with primary and recurrent gastric cancer. Anticancer Res 27: 1207-1212
30. Tomita H, Ichikawa D, Ikoma D, Sai S, Tani N, Ikoma H, Fujiwara H, Kikuchi S, Okamoto K, Ochiai T, Otsuji E (2007) Quantification of circulating plasma DNA fragments as tumor markers in patients with esophageal cancer. Anticancer Res 27: 2737-2741 (Pubitemid 47227990)